EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and broker, N+1 Singer.
Presentation to institutional investors by Julian Baines and Mike Salter.
Launch of Restricted Offer
EKF Diagnostics provides a further update regarding its forthcoming changes to the board of directors of the Company and its planned, final performance related payments to the Company’s Chief Executive Officer and Finance Director.
Strong trading continues into Q2, upgrading full year expectations. Growth Plans & Managed Succession
Trellus Health plc proposed placing, subscription and restricted offer.
Further to the announcement on 23 April 2021.
Adam Reynolds, Non-Executive Director, has sold a total of 500,000 ordinary shares.
EKF Diagnostics Holdings plc confirms that the Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting have now been published.